News
June 18, 2019

Regenstrief scientist explains how class of drugs may be related to dementia

Regenstrief research scientist Noll Campbell, PharmD, M.S., spoke about a common class of drugs and how it affects the brain on an Indianapolis radio show.

Dr. Campbell was a guest on Caregiver Crossing, which airs every Saturday on 93.1 WIBC. Dr. Campbell addressed the topic of anticholinergics and their potential link to Alzheimer’s and dementia. Anticholinergics are a common class of drug that includes some allergy medications, sleeping pills and many more common medicines.

Dr. Campbell recently received a $3.3 million grant from the National Institute on Aging to conduct the first clinical trial designed to determine if stopping these medications results in sustained improvements in cognition.

Listen to his discussion with the Caregiver Crossing hosts and his advice for people who are taking these medications.

Segment 1

Segment 2

Click here for more information on Caregiver Crossing.

  • Noll Campbell, PharmD, MS

Related News

Arthur H. Owora, PhD

Predictive correlates of poor sleep associated with increased risk of severe asthma exacerbations among children with moderate-to-severe asthma

Published in Pediatric Allergy and Immunology. Here is a link to the article. Regenstrief Institute author: Arthur H. Owora,

Atlanta City Skyline

Regenstrief Institute experts will lead presentations, participate in panels at the AMIA 2025

Regenstrief Institute informaticians and other data experts will share their research insights and innovations from November 15-19 during the

Kathleen Unroe, M.D.

Barriers to Discharge for Nursing Home Residents With Serious Mental Illness

Published in the JAMA Network Open. Here is a link to the article. Regenstrief Institute authors: Kathleen T. Unroe,

Building a Learning Health System to Support Older Veterans

Regenstrief authors: Dawn M. Bravata, M.D. and Nicholas A. Rattray, PhD  Published in the Journal of General Internal Medicine.